Follow us...


Search News Archives

News Channels


New Laboratory Products

Lab News

Research & Case Studies

Microscopy | Image Analysis

Separation Science

Brochures & Literature


Events | Webinars



Conferences | Events
3P Biopharmaceuticals

3P Biopharmaceuticals

3P Biopharmaceuticals


Contact 3P Biopharmaceuticals

If you have not logged into the website then please enter your details below.

All articles from 3P Biopharmaceuticals

  3P Biopharmaceuticals will participate in a major European Project aiming to develop a universal influenza virus vaccine.

3P Biopharmaceuticals will participate in the European research project FLUTCORE, financed by the European Union 7th Framework Programme (FP7). The consortium is comprised of several prestigious companies and research centers specialized in influenza virus research.

3P BiopharmaceuticalsThe European consortium will be led by iQur Ltd., which is a biotech company based in London, whose research into the tandem core™ vaccine platform forms the basis of the science behind the project. Their vaccine platform has been shown to generate powerful immune responses to several pathogens and this consortium will optimize their influenza candidate vaccine for use in the clinical setting.




Media Partners